menu
    • menu
    [{"orgOrder":0,"company":"Cornerstone Therapeutics Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Zileuton","moa":"Arachidonate 5-lipoxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Cornerstone Therapeutics Inc.","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Cornerstone Therapeutics Inc. \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Cornerstone Therapeutics Inc. \/ Undisclosed"},{"orgOrder":0,"company":"University of Massachusetts, Worcester","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Zileuton","moa":"Arachidonate 5-lipoxygenase","graph1":"Oncology","graph2":"Phase I","graph3":"University of Massachusetts, Worcester","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Massachusetts, Worcester \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"University of Massachusetts, Worcester \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Novateur Ventures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Zileuton","moa":"||Arachidonate 5-lipoxygenase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Novateur Ventures","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novateur Ventures \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Novateur Ventures \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Zileuton

    Menu

    Zileuton

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Novateur Ventures

                            Canada arrow
                            CPhI India
                            Not Confirmed

                            Novateur Ventures

                            Canada arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zileuton,Montelukast Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Novateur Study Points Toward Potential COVID-19 Treatment

                            Details : Novateur proposes a simple treatment paradigm using a combination of a leukotriene biosynthesis blocker, Zyflo® controlled release formulation and an inhibitor of the cysteinyl leukotriene 1 receptor, Singulair® to target the hyper-inflammatory respons...

                            Product Name : Zyflo

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 06, 2020

                            Lead Product(s) : Zileuton,Montelukast Sodium

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Massachusetts, Worcester

                            Country arrow
                            CPhI India
                            Not Confirmed

                            University of Massachusetts, Worcester

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zileuton

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogeno...

                            Details : Zileuton is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 28, 2014

                            Lead Product(s) : Zileuton

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cornerstone Therapeutics Inc.

                            Country arrow
                            CPhI India
                            Not Confirmed

                            Cornerstone Therapeutics Inc.

                            Country arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zileuton

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Single Dose Bronchodilatory Study in Asthma

                            Details : Zileuton is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Asthma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 06, 2013

                            Lead Product(s) : Zileuton

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth